(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ACT-IG

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

ACT-IG

ST13

US500000079277722

Classe

5, 42, 45

Pedido

79277722

Registro

6610076

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

50

Atualização mais recente

02/09/2022

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5, 42, 45

Data de depósito

25/09/2019

Data de registro

11/01/2022

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

11/01/2022

Última transação

02/09/2022

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

03

Localização do titular

JP

Examinador

ALLEN, BIANCA

Unidade examinadora

N50

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

CHUGAI SEIYAKU KABUSHIKI KAISHA (Chugai Pharmaceutical Co., Ltd.)

Representantes

BASSAM N IBRAHIM BUCHANAN INGERSOLL & ROONEY PC

Classificação técnica

Classes Nice

Classe 5Classe 42Classe 45

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical preparations for human usepharmaceutical antibodies and their fragments and derivativescells and genes that produces antibodiesfragments of antibodies and derivatives of antibodiesall for preventing or treating infectious and parasitic diseasescancerblood and blood-forming organs diseases and disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systempregnancychildbirth and the puerperiumcongenital malformationsdeformations and chromosomal abnormalitiesfor medical and pharmaceutical use

Classe 42

Pharmaceutical research and development services and providing information about medical and scientific research in the field of pharmaceuticals

Classe 45

Granting of licenses to others for the use of industrial property rights and copyright

Publicações

Histórico de despachos e eventos da marca no USPTO.

50 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

01/08/2022

XXSS

GENERIC MADRID TRANSACTION SENT TO IB

24/06/2022

XXCR

GENERIC MADRID TRANSACTION CREATED

23/06/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

11/04/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

11/01/2022

GPNX

NOTIFICATION PROCESSED BY IB

04/11/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

26/10/2021

PUBO

PUBLISHED FOR OPPOSITION

26/10/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

06/10/2021

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

06/10/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

06/10/2021

EXPT

EXPARTE APPEAL TERMINATED

18/09/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

17/09/2021

XAEC

EXAMINER'S AMENDMENT ENTERED

17/09/2021

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

17/09/2021

GNEA

EXAMINERS AMENDMENT E-MAILED

17/09/2021

CNEA

EXAMINERS AMENDMENT -WRITTEN

17/09/2021

DOCK

ASSIGNED TO EXAMINER

03/08/2021

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

24/07/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

07/07/2021

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

07/07/2021

JURT

JURISDICTION RESTORED TO EXAMINING ATTORNEY

23/06/2021

GEA1

NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED

08/04/2021

GECD

ACTION DENYING REQ FOR RECON E-MAILED

08/04/2021

CNCF

ACTION CONTINUING FINAL - COMPLETED

08/04/2021

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

19/03/2021

EXPI

EX PARTE APPEAL-INSTITUTED

19/03/2021

JURT

JURISDICTION RESTORED TO EXAMINING ATTORNEY

19/03/2021

EXAF

EXPARTE APPEAL RECEIVED AT TTAB

19/03/2021

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

26/09/2020

GNFR

FINAL REFUSAL E-MAILED

26/09/2020

CNFR

FINAL REFUSAL WRITTEN

26/09/2020

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/09/2020

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/09/2020

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

08/09/2020

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

31/03/2020

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

31/03/2020

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

31/03/2020

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

31/03/2020

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

31/03/2020

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

31/03/2020

RFNT

REFUSAL PROCESSED BY IB

21/03/2020

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

05/03/2020

RFRR

REFUSAL PROCESSED BY MPU

05/03/2020

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

12/02/2020

CNRT

NON-FINAL ACTION WRITTEN

11/02/2020

MAFR

APPLICATION FILING RECEIPT MAILED

11/02/2020

DOCK

ASSIGNED TO EXAMINER

07/02/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/02/2020

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

06/02/2020

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ACT-IG ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.